Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Mark Tepper
AddedFeb 15, 2024
UpdatedMay 31, 2026
Mark Tepper

Mark Tepper

CEO, Eumentis Therapeutics

CrunchbaseLinkedInThe Org

Mark Tepper's Career

Eumentis Therapeutics
Eumentis Therapeutics

Boston, MA, US

CEO· C-Suite · Management
NKT Therapeutics
NKT Therapeutics

Waltham, MA, US

Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Mark Tepper's Career

Eumentis Therapeutics
Eumentis Therapeutics
Seed$8.9M52019Boston, MA, US
CEO· C-Suite · Management

Leadership at Eumentis Therapeutics

Xiaoming ZhangXiaoming ZhangCo-Founder
Andrew MendelsohnAndrew MendelsohnCo-Founder

Similar to Eumentis Therapeutics

Embera NeurotherapeuticsEmbera NeurotherapeuticsSudbury, MA, USPharmaceuticalsest. 2005Embera NeurotherapeuticsSudbury, MA, US · est. 2005

Embera NeuroTherapeutics: Pioneering targeted addiction treatments in the US pharmaceutical sector.

Series A · $28.4M11
Euthymics BioscienceEuthymics BioscienceCambridge, MA, USPharmaceuticalsest. 2009Euthymics BioscienceCambridge, MA, US · est. 2009

Euthymics Bioscience: A neuroscience-focused company developing advanced treatments for depression and CNS disorders.

Series A · $38.5M30
NeuroPro TherapeuticsNeuroPro TherapeuticsYachats, OR, USPharmaceuticalsest. 2014NeuroPro TherapeuticsYachats, OR, US · est. 2014

NeuroPro Therapeutics: Developing pharmaceutical solutions for epilepsy and neurological disorders.

Series A · $5.1M5
NeuroTherapeutics PharmaNeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30
NKT Therapeutics
NKT Therapeutics
Series A$12M82008Waltham, MA, US
Founder

Leadership at NKT Therapeutics

Mike RossMike RossBoard Member
Robert MashalRobert MashalBoard Member
Dr Samuel Wu \"Sam\"Dr Samuel Wu \"Sam\"Board Member

Similar to NKT Therapeutics

Nektar TherapeuticsNektar TherapeuticsSan Francisco, CA, USTherapeuticsest. 1990Nektar TherapeuticsSan Francisco, CA, US · est. 1990

Nektar Therapeutics, an American healthcare company, innovates polymer-based therapeutics.

Public · $1.2B216
NeuroTherapeutics PharmaNeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30
Nuon TherapeuticsNuon TherapeuticsSan Mateo, CA, USTherapiesest. 2002Nuon TherapeuticsSan Mateo, CA, US · est. 2002

Nuon Therapeutics: A US-based biotech firm innovating therapies for autoimmune and inflammatory diseases.

Series A · $48M75

Mark Tepper's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · Kakao

People Similar to Mark Tepper

Michael CharestMichael CharestCo-Founder · RewardixLaurence SotskyLaurence SotskyBoard Member · IncentifyRajat BhakhriRajat BhakhriCo-Founder · IncentivioAdam ShepherdAdam ShepherdCo-Founder · IncentivyzeBrett MarkinsonBrett MarkinsonFounder · Innovent Capital GroupSanjib JhaSanjib JhaCo-Founder · Avaana Capital